Loading…
Galmed Pharmaceuticals Ltd., A Biopharmaceutical Company, Focuses On The Development Of Therapeutics For The Treatment Of Liver Diseases. It Develops Aramchol, A First-In-Class Synthetic Fatty Acid-Bile Acid Conjugate Molecule Which Is In Phase Iii Study For Oral Treatment For Non-Alcoholic Steato-Hepatitis (Nash) In Patients Who Are Overweight Or Obese And Have Prediabetes Or Type Ii Diabetes Mellitus. The Company Also Evaluates Aramchol Through Arrive Study, A Phase Iia Clinical Trial With Hiv-Associated Non-Alcoholic Fatty Liver Disease And Lipodystrophy. In Addition, It Engages In The Development Of Amilo-5mer, A 5 Amino Acid Synthetic Peptide Methionine, Threonine, Alanine, Aspartic Acid, And Valine. Further, The Company Develops Mybiotics Which Is In Pre-Clinical Trials For Nash And Fibrosis. It Has A License Agreement With Samil Pharma. Co., Ltd. For The Commercialization Of Aramchol In The Republic Of Korea; And A Collaboration Agreement With Onkai For Its Ai Platform. Galmed Pharmaceuticals Ltd. Was Founded In 2000 And Is Headquartered In Ramat Gan, Israel.